Impact of Routine Follow-Up Examinations on Life Expectancy in Ovarian Cancer Patients: A Simulation Study
- 1 September 2012
- journal article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 22 (7), 1150-1157
- https://doi.org/10.1097/igc.0b013e3182611451
Abstract
Objective The clinical benefit of routine follow-up in patients treated for ovarian cancer is subject to debate. In this study, the magnitude of the potential survival benefit of routine examinations was evaluated by Markov modeling. Methods The clinical course of ovarian cancer was simulated using a 4-state nonstationary Markov model. Risk of recurrence and mortality probabilities were derived from individual patient data and Statistics Netherlands. The life expectancy was simulated for 3 follow-up scenarios: a current, withholding (all recurrences detected symptomatically), and perfect follow-up program (all recurrences detected asymptomatically). The impact of effective recurrence treatment in the future was modeled by varying the mortality ratio between patients with asymptomatically versus symptomatically detected recurrences. The model was validated using empirical data. Results The mean life expectancy of patients, aged 58 years and in complete clinical remission after primary treatment, was 10.8 years. Varying the transition probabilities with ±25% changed the life expectancy by up to 1.1 years. The modeled life expectancy for the withholding and perfect follow-up scenarios was also 10.8 years and insensitive to model assumptions. In patients with stages IIB to IV, the life expectancy was 7.0 years, irrespective of follow-up strategy. A mortality ratio of 0.8 for patients with asymptomatically versus symptomatically detected recurrences resulted in a gain in life expectancy of 5 months for withholding versus perfect follow-up. Conclusions Routine follow-up in ovarian cancer patients is not expected to improve the life expectancy. The timing of detection of recurrent ovarian cancer is immaterial until markedly improved treatment options become available.Keywords
This publication has 21 references indexed in Scilit:
- Considering Early Detection of Relapsed Ovarian CancerInternational Journal of Gynecologic Cancer, 2011
- No Supportive Evidence for Clinical Benefit of Routine Follow-Up in Ovarian Cancer: A Dutch Multicenter StudyInternational Journal of Gynecologic Cancer, 2011
- CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based studyGynecologic Oncology, 2010
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialThe Lancet, 2010
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric StudyInternational Journal of Gynecologic Cancer, 2009
- Optimal Chemotherapy Treatment for Women with Recurrent Ovarian CancerCurrent Oncology, 2007
- Effect of routine follow‐up after treatment for laryngeal cancer on life expectancy and mortalityCancer, 2007
- Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: A simulation studyAnnals of Oncology, 2001
- A convenient approximation of life expectancy (the “DEALE”): I. validation of the methodAmerican Journal Of Medicine, 1982